Dr. Benjamin Levy, Mount Sinai Health Systems, discusses platinum-based chemotherapy as the standard of care for advanced NSCLC patients without targetable genetic mutations.

Transcript

I think there are several goals when treating a patient with advanced non-small cell lung cancer. For one I think we want to extend life, two is I think we want to palliate symptoms, and three is I think we want to improve quality of life. So all three of those goals are achievable, I think, with the therapies that we have right now.

The Northwest Medical Development Therapeutics Institute is breaking new ground by conducting clinical trials that will test treatments based on tumor mutations, rather than where the tumor began. Dr. Melissa Johnson describes the work of the center.

[powerpress]

A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.

[powerpress]

How much detail is needed when determining how to treat lung cancer? Should patients be tested for all the mutations that may exist within their tumors? Dr. Jonathan Riess discusses this issue and how he makes decisions regarding his own patients.

[powerpress]

When it comes to EGFR and lung cancer, is a mutation good or bad? Dr. Joel Neal of Stanford University Medical Center explains why non-mutated genes are called "wild type." February 2014.

[powerpress]